Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-04-04
2006-04-04
Ungar, Susan (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S277100, C424S184100, C424S185100, C536S023100
Reexamination Certificate
active
07022819
ABSTRACT:
The invention relates to isolated nucleic acid molecules which code for antigens expressed by tumor cells which maybe recognized by cytotoxic T cells, leading to lysis of the tumor cells which express it. This invention also relates to vectors which are designed to encode the antigen expressed by tumor cells and also to cells transfected by the nucleic acid molecules or vectors which comprise the nucleic acid molecules. Various therapeutic and diagnostic uses arising out of the properties of the nucleic acid molecules and the antigens for which these code are also part of this invention.
REFERENCES:
patent: 4889806 (1989-12-01), Olson
patent: 5342774 (1994-08-01), Boon
patent: 5405940 (1995-04-01), Boon
patent: 5462871 (1995-10-01), Boon-Falleur
patent: 5487974 (1996-01-01), Boon-Falleur
patent: 5554506 (1996-09-01), van der Bruggen .
patent: 5554724 (1996-09-01), Melief
patent: 5750395 (1998-05-01), Fikes et al.
patent: WO-94/03205 (1994-02-01), None
Schmid S et al, 2001, J comparative Neurology, 430(2): 160-71.
Conner et al, 1996, Mol Brain Res, 42: 1-17.
MPSRCH search report, 2005, us-10-160-237-18.rai, pp. 3-4.
DATABASE EMBL, Tumour rejection antigen MAGE-4 gene Database accession no. AAQ72482 XP002221384, Oct. 13, 1994.
DATABASE EMBL, MZ2-MEL antigen E precursor, Database accession no. AAT05086 XP002221385, Sep. 8, 1995.
Lucas Sophie et al., Identification of a new MAGE gene with tumor-specific expression by representational difference analysis, Cancer Research, vol. 58, No. 4, pp. 743-752, Feb. 15, 1998.
Chen et al., Identification of multiple cancer/testis antigens by allogenic antibody screening of a melanoma cell line library. Proceedings of the National Academy of Sciences of USA, National Academy of Science. vol. 95, pp. 6919-6923, Jun. 1998.
Townsend et al., “The Epitopes of Influenza Nucleoprotein Recognized by Cytotoxic T Lymphocytes Can Be Defined With Short Synthetic Peptides”, Cell, 44: 959-968 (1986).
Bjorkman et al., “The foreign antigen binding site and T cell recognition regions of class I histocompatibility antigen”, Nature, 329: 512-518 (1987).
Van der Bruggen et al., “A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma”, Science 254: 1643-1647 (1991).
Traversari et al., “A Nonapeptide Encoded by Human Gene MAGE-1 Is Recognized on HLA-A1 by Cytolytic T Lymphocytes Directed Againstst Tumor Antigen MZ2-E”, J. Exp. Med. 176: 1453-1457 (1992).
Ruppert et al., “Prominent Role of Secondary Anchor Residues in Peptide Binding to HLA-A2.1 Molecules”. Cell 74: 929-937 (1993).
Celis et al., “Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes”, Proc. Natl. Acad. Sci. USA 91: 2105-2109 (1994).
Coulie et al., “A New Gene Coding For A Differentiation Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas”, J. Exp. Med. 180: 35-42 (1994).
Engelhard et al., “Structure of Peptides Associated With Class I and Class II MHC Molecules”, Ann. Rev. Immunol. 12: 181-207 (1994).
DeSmet et al., “Sequence and expression pattern of the human MAGE-2 gene”, Immunogenitc 39: 121-129 (1994).
Ding, et al., “Cloning And Analysis of MAGE-1 Related Genes”, Biochem & Biophys. Res. Commun. 202(1): 549-555 (1994).
Van der Bruggen, et al., “A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3”, Eur. J. Immunol. 24: 3038-3043 (1994).
A.G. Dalgleish, et al., “Tumor Immunology”, Cancer Clinical Science in Practice, (1994).
De Plaen, et al., “Structure, chromosomal localization, and expression of 12 genes of the Mage family”, Immunogenetics 40: 360-369 (1994).
M. Hubank, et al., “Identifying differences in mRNA expression by representational difference analysis of cDNA”, Nucleic Acids Research 22: 25:5640-5648 (1994).
De Plaen et al., Accessio No. U10685.
Harris et al. “J. of The Am Society of Nephrology” 65: 1125-1133 (1995).
Ahn et al. Nature Genetics 3(4): 283-291 (1993).
Cawthon et al. Genomics 9(3): 446-460 (1991).
De Plaen Immunogenetics, 40: 360-369 (1994).
Bowie et al., Science 257: 1306-1310 (1990).
Burgess et al. J. Of Cell Bio. 111: 2129-2138 (1990).
Lazar et al. Molecular and Cellular Biology, 8: 1247-1252 (1988).
Bork, Genome Research, 10: 398-400 (2000).
Sambrook et al., “Molecular Cloning”, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Press, Cold Spring Harbor, p. 16.3-16.4.
Boon-Falleur Thierry
De Smet Charles
Lucas Sophie
Davis Minh-Tam
Fulbright & Jaworski
Ludwig Institute for Cancer Research
Ungar Susan
LandOfFree
Isolated nucleic acid molecule coding for tumor rejection... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isolated nucleic acid molecule coding for tumor rejection..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated nucleic acid molecule coding for tumor rejection... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3543109